Doribax doripenem regulatory update

FDA updated the label of Doribax doripenem from Shionogi to include information related to the increased risk of mortality in patients with ventilator-associated bacterial pneumonia (VABP) receiving the broadspectrum carbapenem antibiotic. Doribax is approved in the U.S. to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI); it is not approved in the U.S. to treat pneumonia. ...